Liege, Belgium - Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the 'Company' or 'Mithra'), a company dedicated to women's health, announces that it completed the private placement of 3,871,491 new shares for an aggregate amount of EUR 23.5 million that it had announced on 21 June 2022 (the 'Private Placement').
As a result of the completion of the Private Placement, the share capital of the Company was increased from EUR 33,739,072.34 to EUR 36,573,390.90 and the number of issued and outstanding shares of the Company was increased from 46,085,634 to 49,957,125 ordinary shares, through the issuance of a total of 3,871,491 new shares at an issue price of EUR 6.07 per new share.
New denominator
Following the completion of the Private Placement, and in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, the amount of the Company's outstanding share capital and the number of outstanding securities and voting rights are as follows: * Capital: EUR 36,573,390.90 * Total number of securities carrying voting rights: 49,957,125 (all ordinary shares) * Total number of voting rights (= denominator): 49,957,125 (all relating to ordinary shares) * Number of outstanding rights to subscribe to securities carrying voting rights: o Pursuant to the share option plan of 5 November 2018: 1,394,900 subscription rights giving right to 1,394,900 ordinary shares o Pursuant to the share option plan of 22 July 2020 : 690,000 subscription rights giving right to 690,000 ordinary shares o Pursuant to the share option plan granted to the lending shareholders of 7 September 2020: 300,000 subscription rights giving right to 300,000 ordinary shares o Pursuant to the share option plan of 20 November 2020: 390.717 subscription rights giving rise to 390.717 ordinary shares.
The new shares that were issued have the same rights and benefits as, and rank pari passu in all respects, including as to entitlement to dividends and distributions, with, the existing and outstanding shares of Mithra, and are entitled to dividends and distributions in respect of which the relevant record date or due date falls on or after the date of issue of the new shares.
Contact:
Christophe Marechal
CFO
T: +32 495 55 14 78
E: investorrelations@mithra.com
About Mithra
Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrolbased product in 2021, the contraceptive pill Estelle, Mithra is now focusing on its second product Donesta, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormonedependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liege, Belgium. www.mithra.com
MITHRA PHARMACEUTICALS S.A. 
